Evidence map›Paper›PMID 33947268›Full record

ArticleAIDS research and human retroviruses2022

Considerations for Increasing Racial, Ethnic, Gender, and Sexual Diversity in HIV Cure-Related Research with Analytical Treatment Interruptions: A Qualitative Inquiry.

Karine Dubé, John Kanazawa, Chadwick Campbell, Cheriko A Boone, Allysha C Maragh-Bass, Danielle M Campbell, Moisés Agosto-Rosario, Jamila K Stockman, Dázon Dixon Diallo, Tonia Poteat and 3 more

Open access · greenAbstract read
In one paragraph

Article in AIDS research and human retroviruses, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed, 2 pooled it
2.5field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 2 syntheses or guidelines pooled it, 52 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. The HIV Reservoir and Immune Landscape Across the Life Course of Women: Implications for Cure Strategies.American journal of reproductive immunology (New York, N.Y. : 1989) · 2026
    Review
  6. Observational
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Observational
  18. Article
  19. Building a diverse national research advisory board.Journal of clinical and translational science · 2025
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 8 institutions in 1 country.

Karine DubéGillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.ORCID 0000-0003-3458-1539
John KanazawaGillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.ORCID 0000-0001-7064-6657
Chadwick CampbellDivision of Prevention Sciences, Department of Medicine, Center for AIDS Prevention Studies (CAPS), University of California, San Francisco (UCSF), San Francisco, California, USA.ORCID 0000-0002-8609-5762
Cheriko A BooneDepartment of Psychological and Brain Sciences, George Washington University, Washington, District of Columbia, USA.
Allysha C Maragh-BassBehavioral, Epidemiological, and Clinical Sciences, FHI 360, Durham, North Carolina, USA.
Danielle M CampbellCharles R. Drew University of Medicine and Science, Los Angeles, California, USA.
Moisés Agosto-RosarioNational Minority AIDS Council (NMAC), Washington, District of Columbia, USA.
Jamila K StockmanDivision of Infectious Diseases and Global Public Health, Department of Medicine, University of California, San Diego, San Diego, California, USA.
Dázon Dixon DialloSisterLove, Inc., Atlanta, Georgia, USA.
Tonia PoteatDepartment of Social Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.ORCID 0000-0001-6541-3787
Mallory JohnsonDivision of Prevention Sciences, Department of Medicine, Center for AIDS Prevention Studies (CAPS), University of California, San Francisco (UCSF), San Francisco, California, USA.
Parya SaberiDivision of Prevention Sciences, Department of Medicine, Center for AIDS Prevention Studies (CAPS), University of California, San Francisco (UCSF), San Francisco, California, USA.
John A SaucedaDivision of Prevention Sciences, Department of Medicine, Center for AIDS Prevention Studies (CAPS), University of California, San Francisco (UCSF), San Francisco, California, USA.
San Francisco AIDS Foundation · USUniversity of North Carolina at Chapel Hill · USCharles R. Drew University of Medicine and Science · USFamily Health International 360 · USGeorge Washington University · USNational Minority AIDS Council · USUniversity of California San Diego · USUniversity of California, San Francisco · US

Funding

First-in-human study of two anti-SARS CoV-2 antibodies in health volunteersUM1AI126620 · NIAID · WISTAR INSTITUTE · PI MONTANER, LUIS J, RILEY, JAMES L. · 2016 to 2021
$24.5M
Research Services CoreP2CHD050924 · NICHD · UNIV OF NORTH CAROLINA CHAPEL HILL · PI KAREN B GUZZO · 2015 to 2026
$9.6M
Training Program in Substance Use, HIV and Related InfectionsT32DA023356 · NIDA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Natasha Martin, Steffanie A Strathdee · 2007 to 2026
$7.8M
Training Program for Scientists Conducting Research to Reduce HIV Health DisparitR25MH067127 · NIMH · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Emily A Arnold, Torsten Brian Neilands · 2003 to 2026
$5.4M
Mentoring and Empowerment in the Context of HIV Care for At-Risk PopulationsK24DA037034 · NIDA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI JOHNSON, MALLORY O · 2014 to 2018
$918k
Pilot Integration of Participant-Centered Outcomes in HIV Cure Research in the United States: Implications for Ethical ConductR21MH118120 · NIMH · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DUBE, KARINE · 2019 to 2020
$566k
Perceptions of Risks and Benefits of Participating in HIV Cure-related Research among Diverse Youth and Young Adults Living with HIV in the United StatesR21MH122280 · NIMH · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI DUBE, KARINE, SABERI, PARYA · 2020 to 2021
$458k
NIAID NIH HHS UM1 AI126620NICHD NIH HHS P2C HD050924NIDA NIH HHS K24 DA037034NIDA NIH HHS T32 DA023356NIMH NIH HHS R21 MH118120NIMH NIH HHS R21 MH122280NIMH NIH HHS R25 MH067127
6 · The paper itself

Abstract

Despite disproportionate incidence and prevalence of HIV among transgender individuals, cisgender women, and racial and ethnic minority groups, all remain underrepresented in HIV cure research. As HIV cure trials are scaled up, there is emerging research on ways to mitigate risks of HIV acquisition for sexual partners of analytical treatment interruption (ATI) trial participants. As such, it is imperative that HIV cure researchers consider the implications of implementing ATIs in populations that are disproportionately affected by HIV, but largely underrepresented in trials to date. In this qualitative study, we sought to derive triangulated perspectives on the social and ethical implications regarding ATIs and partner protection strategies during ATIs among under-represented populations. We conducted 21 in-depth interviews with 5 types of informants: bioethicists, community members [people living with HIV (PLWH) and their advocates], biomedical HIV cure researchers, sociobehavioral scientists, and HIV care providers. We analyzed the data using conventional content analysis and reduced the data to important considerations for implementing ATI trials in diverse communities and settings. Our study revealed the following key themes: (1) attention must be paid to gender and power dynamics in ATI trials; (2) ATI trials should be designed and implemented through the lenses of intersectionality and equity frameworks; (3) ATI trials may have both positive and negative effects on stigma for PLWH and their partners; and (4) partnership dynamics should be considered when designing ATI protocols. Our study generated actionable considerations that could be implemented in ATI trials to promote their acceptability to communities that have been underrepresented in HIV cure research to date. Research teams must invest in robust community and stakeholder engagement to define best practices. Paying attention to representation and equity will also promote better and more equitable implementation of HIV cure strategies once these become ready for rollout.

Indexed as

EthnicityHIV InfectionsFemaleHumansMinority GroupsQualitative ResearchSexual Partnersanalytical treatment interruptionHIVHIV cure researchminoritiespartner protectionpeople living with HIVrace and ethnicitytransgender womenwomen

Identifiers

PMID33947268
PMCPMC8785755
OpenAlexW3157812955

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.